

**IN THE CLAIMS:**

The current claim set should now replace any claim set of record.

Claim 1.     **(Canceled)**

Claim 2.     **(Previously presented)** The nucleic acid described in claim 17, wherein the nucleic acid is an RNA.

Claim 3.     **(Previously presented)** The nucleic acid described in claim 17, wherein the nucleic acid is a cDNA.

Claim 4.     **(Canceled)**

Claim 5.     **(Currently amended)** ~~The A purified nucleic acid described in claim 18, wherein the nucleic acid molecule selected from the group consisting of:~~  
~~(A) a nucleic acid molecule that~~ consists of a sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:10;  
~~and~~  
~~(B) the complete full-length complement of said nucleic acid molecule~~  
~~(A).~~

Claim 6.     **(Withdrawn)** A polypeptide encoded by a nucleic acid comprising the sequence given in SEQ ID NO:1 or the sequence given in SEQ ID NO:3.

Claim 7.     **(Withdrawn)** The polypeptide described in claim 6, wherein the polypeptide is a recombinantly produced polypeptide.

Claim 8.     **(Withdrawn)** An antibody that binds immunospecifically with a polypeptide encoded by a nucleic acid comprising a sequence given in SEQ ID NO: 1 or a sequence given in SEQ ID NO:3.

Claim 9.     **(Canceled)**

- Claim 10. **(Previously presented)** The method described in claim 19, wherein the sample is blood, urine or seminal fluid.
- Claim 11. **(Canceled)**
- Claim 12. **(Previously presented)** The method described in claim 19, wherein the determining step comprises amplifying the nucleic acid and detecting the amplified nucleic acid.
- Claim 13. **(Withdrawn)** A method of detecting precancerous cells or cancer cells in the prostate of a subject, said method comprising providing a sample of tissue or fluid from the subject and determining whether the sample contains an abnormally high content of a polypeptide encoded by a nucleic acid comprising a sequence given in SEQ ID NO:1 or SEQ ID NO:3, whereby determining that the sample contains an abnormally high content of the polypeptide indicates that the subject has precancerous cells or cancer cells in the prostate.
- Claim 14. **(Withdrawn)** The method described in claim 13, wherein the sample is a body fluid.
- Claim 15. **(Withdrawn)** The method described in claim 13, wherein the sample is tissue originating from the prostate.
- Claim 16. **(Withdrawn)** The method described in claim 13, wherein the determining step further comprises contacting at least a portion of the sample with an antibody that binds immunospecifically with the polypeptide and determining the amount of the antibody that has bound with the polypeptide present in the sample.
- Claim 17. **(Currently amended)** A purified nucleic acid molecule selected from the group consisting of:  
(A) a nucleic acid molecule that comprises the sequence of SEQ ID NO:1; and

- (B) ~~a nucleic acid molecule that comprises a sequence that is completely complementary to the full length sequence the complete full-length complement~~ of said nucleic acid molecule (A).

Claim 18. **(Canceled)**

Claim 19. **(Currently amended)** A method of detecting prostate cancer in a subject, said method comprising the steps:

- (A) obtaining a sample ~~of prostate tissue from a primary prostate tumor or blood, urine or seminal fluid~~ from said subject, and
- (B) determining whether said sample contains an increased ~~content level~~ compared to a normal control of a nucleic acid molecule selected from the group consisting of:
- (1) ~~a the nucleic acid molecule that comprises the sequence of SEQ ID NO:1; and~~
- (2) ~~a nucleic acid molecule that comprises a sequence that is completely complementary to the full length sequence the complete full-length complement~~ of said nucleic acid molecule (1);

wherein detection of said increased content level of said nucleic acid molecule is indicative of the presence of prostate cancer in said subject.

Claims 20-24 **(Canceled)**

Claim 25. **(Canceled)**

Claim 26. **(Canceled)**

Claim 27. **(Currently amended)** A purified nucleic acid molecule selected from the group consisting of:

- (A) ~~a the nucleic acid molecule that comprises the sequence of nucleotide 77 through nucleotide 1753 of SEQ ID NO:1; and~~

- (B) ~~a nucleic acid molecule that comprises a sequence that is completely complementary to the full length sequence the complete full-length complement~~ of said nucleic acid molecule  
(A).

Claim 28. **(Previously presented)** The nucleic acid described in claim 27, wherein the nucleic acid is an RNA.

Claim 29. **(Previously presented)** The nucleic acid described in claim 27, wherein the nucleic acid is a cDNA.

Claim 30. **(Currently amended)** A method of detecting prostate cancer in a subject, said method comprising the steps:

- (A) obtaining a sample ~~of prostate tissue from a primary prostate tumor~~ or blood, urine or seminal fluid from said subject, and  
(B) determining whether said sample contains an increased ~~content level~~ compared to ~~a normal control~~ of a nucleic acid molecule selected from the group consisting of:  
(1) ~~a the~~ nucleic acid molecule that comprises the sequence of nucleotide 77 through nucleotide 1753 of SEQ ID NO:1; and  
(2) ~~a nucleic acid molecule that comprises a sequence that is completely complementary to the full length sequence the complete full-length complement~~ of said nucleic acid molecule (1);

wherein detection of said increased ~~content level~~ of said nucleic acid molecule is indicative of the presence of prostate cancer in said subject.

Claim 31 **(Previously presented)** The method described in claim 30, wherein the sample is blood, urine or seminal fluid.

Claim 32. **(Canceled)**

Claim 33. **(Previously presented)** The method described in claim 30, wherein the determining step comprises amplifying the nucleic acid and detecting the amplified nucleic acid.

Claim 34. **(Canceled)**

Claims 35-40. **(Canceled)**